{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:38:17Z","timestamp":1648849097862},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/s11906-005-0073-5","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T02:10:51Z","timestamp":1180059051000},"page":"367-373","source":"Crossref","is-referenced-by-count":4,"title":["Antihypertensive, antiproteinuric therapy and myocardial infarction and stroke prevention"],"prefix":"10.1007","volume":"7","author":[{"given":"Kenneth L.","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"Suppl. 1","key":"73_CR1","first-page":"S1","volume":"43","author":"National Kidney Foundation Kidney Disease Outcomes Quality Initiative","year":"2004","unstructured":"National Kidney Foundation Kidney Disease Outcomes Quality Initiative: K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. K\/DOQI Advisory Board. Am J Kidney Dis 2004, 43(Suppl. 1):S1-S290.","journal-title":"Am J Kidney Dis"},{"key":"73_CR2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","volume":"139","author":"TH Jafar","year":"2003","unstructured":"Jafar TH, Stark PC, Schmid CH, et al.: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244\u2013252.","journal-title":"Ann Intern Med"},{"key":"73_CR3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0735-1097(02)02663-3","volume":"41","author":"G Manjunath","year":"2003","unstructured":"Manjunath G, Tighiouart H, Ibrahim H, et al.: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003, 41:47\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"73_CR4","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, et al.: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296\u20131305.","journal-title":"N Engl J Med"},{"key":"73_CR5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","volume":"123","author":"JC Peterson","year":"1995","unstructured":"Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and progression of renal disease: the Modification of Diet in Renal Disease study. Modification of Diet in Renal Disease (MDRD) Study Group. Ann Intern Med 1995, 123:754\u2013762.","journal-title":"Ann Intern Med"},{"key":"73_CR6","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archinte.163.13.1555","volume":"163","author":"GL Bakris","year":"2003","unstructured":"Bakris GL, Weir MR, Shanifar S, et al.: Effects of blood pressure level on progression of diabetic nephropathy. Arch Intern Med 2003, 163:1555\u20131565.","journal-title":"Arch Intern Med"},{"key":"73_CR7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. Hypertension 2003, 42:206\u20131252.","journal-title":"Hypertension"},{"key":"73_CR8","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456\u20131462.","journal-title":"N Engl J Med"},{"key":"73_CR9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851\u2013860. Report of the principal results of the Irbesartan Diabetic Nephropathy Trial (IDNT), which compared an angiotensin receptor blocker with placebo and a dihydropyridine calcium antagonist (plus, on average 3 to 4 other antihypertensive drugs) on renal end points in type 2 diabetics. Antihypertensive and antiproteinuric properties of irbesartan are highlighted; little information about cardiovascular end points is provided.","journal-title":"N Engl J Med"},{"key":"73_CR10","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr","year":"2002","unstructured":"Wright JT Jr, Bakris G, Greene T, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. African American Study of Kidney Disease and Hypertension Research Group. JAMA 2002, 288:2421\u20132431.","journal-title":"JAMA"},{"key":"73_CR11","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, De Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861\u2013869. Report of the principal results of the Reduction in Endpoints with the Angiotensin Antagonist Losartan (RENAAL) trial, which compared an ARB with placebo (plus, on average 3 other antihypertensive drugs) on renal end points in type 2 diabetics. Antihypertensive and antiproteinuric properties of irbesartan are highlighted; little information about cardiovascular end points is provided.","journal-title":"N Engl J Med"},{"key":"73_CR12","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"GISEN (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Group","year":"1997","unstructured":"GISEN (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Group: Randomised placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuria, non-diabetic nephropathy. Lancet 1997, 349:1857\u20131863.","journal-title":"Lancet"},{"key":"73_CR13","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","volume":"351","author":"AH Barnett","year":"2004","unstructured":"Barnett AH, Bain SC, Bouter P, et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952\u20131961.","journal-title":"N Engl J Med"},{"key":"73_CR14","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","volume":"321","author":"CE Mogensen","year":"2000","unstructured":"Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440\u20131444.","journal-title":"BMJ"},{"key":"73_CR15","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","volume":"63","author":"P Jacobsen","year":"2003","unstructured":"Jacobsen P, Andersen S, Rossing K, et al.: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003, 63:1874\u20131880.","journal-title":"Kidney Int"},{"key":"73_CR16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","volume":"361","author":"N Nakao","year":"2003","unstructured":"Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensinconverting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117\u2013124.","journal-title":"Lancet"},{"key":"73_CR17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","volume":"138","author":"T Berl","year":"2003","unstructured":"Berl T, Hunsicker LG, Lewis JB, et al.: Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003, 138:542\u2013549. Detailed report of the cardiovascular end points observed in IDNT. The renal end points (including proteinuria, as well as the composite primary end point of doubling serum creatinine, end-stage renal disease, or death) were significantly reduced with irbesartan, but this was not the case with the major cardiovascular end points (except heart failure).","journal-title":"Ann Intern Med"},{"key":"73_CR18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/clc.4960280307","volume":"28","author":"PR Kowey","year":"2005","unstructured":"Kowey PR, Dickson TZ, Zhang Z, et al.: Losartan and end-organ protection\u2014Lessons from the RENAAL study. Clin Cardiol 2005, 28:136\u2013142. Detailed report of the cardiovascular end points observed in RENAAL. The renal end points (including proteinuria, as well as the composite primary end point of doubling serum creatinine, end-stage renal disease, or death) were significantly reduced with losartan, but this was not the case with the major cardiovascular end points (except heart failure).","journal-title":"Clin Cardiol"},{"key":"73_CR19","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","volume":"285","author":"LY Agodoa","year":"2001","unstructured":"Agodoa LY, Appel L, Bakris GL, et al.: Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis. African American Study of Kidney Disease and Hypertension (AASK) Study Group. JAMA 2001, 285:2719\u20132728.","journal-title":"JAMA"},{"key":"73_CR20","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","volume":"65","author":"GL Bakris","year":"2004","unstructured":"Bakris GL, Weir MR, Secic M, et al.: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004, 65:1991\u20132002.","journal-title":"Kidney Int"},{"key":"73_CR21","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, et al.: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941\u20131951.","journal-title":"N Engl J Med"},{"key":"73_CR22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators","year":"2000","unstructured":"The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000, 342:145\u2013153. Principal results of the Heart Outcomes Prevention Evaluation trial, which showed very impressive cardiovascular end point reductions with high-dose ramipril (atop whatever other medications were needed) in high-risk patients. Little attention is devoted to the effect of ramipril on blood pressure or proteinuria.","journal-title":"N Engl J Med"},{"key":"73_CR23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","author":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. The HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253\u2013259.","journal-title":"Lancet"},{"key":"73_CR24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","volume":"286","author":"GC Gerstein","year":"2001","unstructured":"Gerstein GC, Mann JEF, Yi Q, et al.: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421\u2013426. Report from the HOPE trial regarding elevated risk in patients with baseline measurements of albuminuria. Little attention is devoted to changes during follow-up in urinary albumin excretion that may have been attributed to ramipril, or their correlation with cardiovascular events.","journal-title":"JAMA"},{"key":"73_CR25","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The LIFE Study Group. Lancet 2002, 359:995\u20131003. Principal results of the Losartan Intervention For Endpoint reduction (LIFE) trial, which showed a significant effect of losartan over atenolol on cardiovascular end points (primarily stroke) in hypertensive patients with left ventricular hypertrophy at baseline. Little attention is devoted to measurements of proteinuria in this report.","journal-title":"Lancet"},{"key":"73_CR26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1067\/mhj.2002.119895","volume":"143","author":"K Wachtell","year":"2002","unstructured":"Wachtell K, Palmieri V, Olsen MH, et al.: Urine albumin\/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy. The LIFE Study. Am Heart J 2002, 143:319\u2013326.","journal-title":"Am Heart J"},{"key":"73_CR27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00004872-200203000-00015","volume":"20","author":"K Wachtell","year":"2002","unstructured":"Wachtell K, Olsen MH, Dahl\u00f6f B, et al.: Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy. The LIFE Study. J Hypertens 2002, 20:405\u2013412.","journal-title":"J Hypertens"},{"key":"73_CR28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.7326\/0003-4819-139-11-200312020-00008","volume":"139","author":"K Wachtell","year":"2003","unstructured":"Wachtell K, Ibsen H, Olsen MH, et al.: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy. The LIFE study. Ann Intern Med 2003, 139:901\u2013906.","journal-title":"Ann Intern Med"},{"key":"73_CR29","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/00004872-200409000-00026","volume":"22","author":"H Ibsen","year":"2004","unstructured":"Ibsen H, Wachtell K, Olsen MH, et al.: Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004, 22:1805\u20131811. Report from the LIFE trial regarding risk for cardiovascular events according to baseline albumin\/creatinine ratio. Little attention is devoted to changes during follow-up in urinary albumin excretion that may have been attributed to losartan, or their correlation with cardiovascular events.","journal-title":"J Hypertens"},{"key":"73_CR30","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","unstructured":"PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033\u20131041.","journal-title":"Lancet"},{"key":"73_CR31","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM, The EUROPA Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (The EUROPA study). Lancet 2003, 362:782\u2013788.","journal-title":"Lancet"},{"key":"73_CR32","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1097\/00004872-200312000-00030","volume":"21","author":"CJ Bulpitt","year":"2003","unstructured":"Bulpitt CJ, Beckett NS, Cooke J, et al.: Results of the pilot study for the Hypertension in the Very Elderly Trial. The Hypertension in the Very Elderly Trial (HYVET) Working Group. J Hypertens 2003, 21:2409\u20132417.","journal-title":"J Hypertens"},{"key":"73_CR33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bmj.37970.629537.0D","volume":"328","author":"M Marre","year":"2004","unstructured":"Marre M, Lievre M, Chatellier G, et al.: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (The DIABHYCAR study). DIABHYCAR Study Investigators. BMJ 2004, 328:495.","journal-title":"BMJ"},{"key":"73_CR34","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","volume":"351","author":"The PEACE Trial Investigators","year":"2004","unstructured":"The PEACE Trial Investigators: Angiotensin-converting\u2014enzyme inhibition in stable coronary artery disease. Prevention of Events with Angiotensin Converting Enzyme inhibition Study Group. N Engl J Med 2004, 351:2058\u20132068.","journal-title":"N Engl J Med"},{"key":"73_CR35","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0002-9149(01)01461-8","volume":"87","author":"B Pitt","year":"2001","unstructured":"Pitt B, O\u2019Neill B, Feldman R, et al.: The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE-inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. QUIET Study Group. Am J Cardiol 2001, 87:1058\u20131063.","journal-title":"Am J Cardiol"},{"key":"73_CR36","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0735-1097(00)00736-1","volume":"36","author":"S MacMahon","year":"2000","unstructured":"MacMahon S, Sharpe N, Gamble G, et al.: Randomised, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other arterial disease. J Am Coll Cardiol 2000, 36:438\u2013443.","journal-title":"J Am Coll Cardiol"},{"key":"73_CR37","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/01.CIR.102.15.1748","volume":"102","author":"KK Teo","year":"2000","unstructured":"Teo KK, Burton JR, Buller CE, et al.: Long-term cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin\/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000, 102:1748\u20131754.","journal-title":"Circulation"},{"key":"73_CR38","first-page":"1937","volume":"52","author":"C Kawai","year":"1994","unstructured":"Kawai C, Yui Y, Hosada S: Large-scale multicenter cooperative study for cardiovascular therapy (Japan Multicenter Investigation of Drugs\/Therapies, J-MIC)-results and perspectives [in Japanese]. Nippon Rinsho 1994, 52:1937\u20131946.","journal-title":"Nippon Rinsho"},{"key":"73_CR39","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2337\/diacare.21.4.597","volume":"21","author":"P Tatti","year":"1998","unstructured":"Tatti P, Pahor M, Byington RP, et al.: Outcome results of the Fosinopril Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:1779\u20131780.","journal-title":"Diabetes Care"},{"key":"73_CR40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713\u2013720.","journal-title":"BMJ"},{"key":"73_CR41","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","volume":"338","author":"RO Estacio","year":"1998","unstructured":"Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998, 338:645\u2013652.","journal-title":"N Engl J Med"},{"key":"73_CR42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611\u2013616.","journal-title":"Lancet"},{"key":"73_CR43","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","volume":"354","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Ekbom T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751\u20131756.","journal-title":"Lancet"},{"key":"73_CR44","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981\u20132997.","journal-title":"JAMA"},{"key":"73_CR45","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","volume":"348","author":"LMH Wing","year":"2003","unstructured":"Wing LMH, Reid CM, Ryan P, et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. Second Australian National Blood Pressure Study Group. N Engl J Med 2003, 348:583\u2013592.","journal-title":"N Engl J Med"},{"key":"73_CR46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","volume":"21","author":"H Lithell","year":"2003","unstructured":"Lithell H, Hansson L, Skoog I, et al.: The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875\u2013886.","journal-title":"J Hypertens"},{"key":"73_CR47","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1161\/01.STR.0000075777.18006.89","volume":"34","author":"J Schrader","year":"2003","unstructured":"Schrader J, Luders S, Kulschewski A, et al.: The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003, 34:1699\u20131703.","journal-title":"Stroke"},{"key":"73_CR48","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen S, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004, 363:2022\u20132031.","journal-title":"Lancet"},{"key":"73_CR49","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","volume":"36","author":"J Schraeder","year":"2005","unstructured":"Schraeder J, Luders S, Kulschewski A, et al.:Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES) MOSES Study Group. Stroke 2005, 36:1218\u20131226.","journal-title":"Stroke"},{"key":"73_CR50","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/00004872-200306000-00002","volume":"21","author":"JA Staessen","year":"2003","unstructured":"Staessen JA, Wang J-G, Thijs L: Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 01 March 2003. J Hypertension 2003, 21:1005\u20131076.","journal-title":"J Hypertension"},{"key":"73_CR51","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"F Turnbull","year":"2003","unstructured":"Turnbull F, Blood Pressure Lowering Treatment Trialists\u2019 Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527\u20131535.","journal-title":"Lancet"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-005-0073-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-005-0073-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-005-0073-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:16:13Z","timestamp":1559434573000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-005-0073-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["73"],"URL":"https:\/\/doi.org\/10.1007\/s11906-005-0073-5","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}